Tumor-Treating Fields Combined with Radiotherapy and Temzolomide for the Treatment of Newly Diagnosed Glioblastoma: Final Results from a Pilot Study

  • Grossman R
  • Bokstein F
  • Ben Harosh C
  • et al.
Citations of this article
Mendeley users who have this article in their library.


Purpose/Objective(s): Tumor Treating Fields (TTFields) are a non‐invasive, loco‐regional, anti‐mitotic treatment comprising low intensity alternating electric fields. In the phase 3 EF‐14 study in newly diagnosed glioblastoma (ndGBM), TTFields significantly improved survival compared to temozolomide (TMZ). Preclinical data have demonstrated that TTFields increased glioma cell death following radiation therapy (RT), suggesting a radio‐sensitizing effect of TTFields. We therefore initiated a pilot study to evaluate the safety and feasibility of administering TTFields concomitant to RT and TMZ in ndGBM patients. Materials/Methods: Patients with histologically confirmed ndGBM were treated with TTFields/RT/TMZ followed by maintenance TTFields and TMZ for up to 24 months. TTFields (200 kHz) were delivered for ≥18 hours/day with removal of the transducer arrays during delivery of RT. TMZ was administered at a dose of 75 mg/m2/daily for 6 weeks and RT at a total dose of 60 Gy. The primary endpoint was safety of the combined TTFields/RT/TMZ; secondary endpoints included progression‐free survival (PFS), overall survival (OS) and toxicity. Adverse events (AEs) were graded according to CTCAE V4.0. Results: Ten patients were enrolled at a single center in Israel between April and December 2017. All patients had recovered from maximal debulking surgery or biopsy. Five patients (50%) had undergone gross total resection while the rest had biopsy only. Median age was 59 and median KPS was 80. Median dose of RT was 60 Gy. Six patients (60%) reported at least one AE. The most common AE was TTFields‐related skin toxicity, reported in 4 patients (40%), all of which were Grade 1–2 in severity. Two patients reported serious AEs (seizures and general deterioration) that were considered unrelated to TTFields. Median PFS with RT/TMZ/TTFields was 10.5 months. Median OS has not yet been reached. Conclusion: The proportion of patients with TTFields‐related skin toxicity was similar to that reported in ndGBM patients in the randomized phase 3 study (52%). No other TTFields‐related toxicities were reported, nor was there an increase in RT‐ or TMZ‐related toxicities as a result of combining TTFields with RT in addition to TMZ. Based on the safety and preliminary efficacy results of this pilot study, a phase 2 randomized study has been initiated to investigate the efficacy of concomitant RT/TMZ/TTFields in 60 ndGBM patients.




Grossman, R., Bokstein, F., Ben Harosh, C., & Ram, Z. (2019). Tumor-Treating Fields Combined with Radiotherapy and Temzolomide for the Treatment of Newly Diagnosed Glioblastoma: Final Results from a Pilot Study. International Journal of Radiation Oncology*Biology*Physics, 105(1), E99. https://doi.org/10.1016/j.ijrobp.2019.06.2288

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free